Abstract Evidence that brain glutamatergic activity is pathologically elevated in bipolar disorder suggests that mood stabilizers are therapeutic in the disease in part by downregulating glutamatergic activity. Such activity can involve the second messenger, arachidonic acid (AA, 20:4n -6). We tested this hypothesis with regard to valproic acid (VPA), when stimulating glutamatergic N-methyl-D-aspartate (NMDA) receptors in rat brain and measuring AA and related responses. An acute subconvulsant dose of NMDA (25 mg/kg i.p.) or saline was administered to unanesthetized rats that had been treated i.p. daily with VPA (200 mg/kg) or vehicle for 30 days. Quantitative autoradiography following intravenous [1-14 C]AA infusion was used to image regional brain AA incorporation coefficients k*, markers of AA signaling. In chronic vehicle-pretreated rats, NMDA compared with saline significantly increased k* in 41 of 82 examined brain regions, many of which have high NMDA receptor densities, and also increased brain concentrations of the AA metabolites, prostaglandin E 2 (PGE 2 ) and thromboxane B 2 (TXB 2 ). VPA pretreatment reduced baseline concentrations of PGE 2 and TXB 2 , and blocked the NMDA induced increases in k* and in eicosanoid concentrations. These results, taken with evidence that carbamazepine and lithium also block k* responses to NMDA in rat brain, suggest that mood stabilizers act in bipolar disorder in part by downregulating glutamatergic signaling involving AA.
Introduction
Valproic acid (VPA, 2-propylpentaenoic acid) is approved as a mood stabilizer for treating bipolar disorder, particularly its manic phase [17, 39, 62] . Although inhibition of GABAergic neurotransmission is considered its major pharmacological action, VPA has many other central effects [43] . It can inhibit histone deacetylase [45] and brain microsomal long-chain fatty acyl-CoA synthethase [12] , increase brain levels of the neuroprotective proteins bcl-2 and brain derived neurotrophic factor [23, 36] , and alter transcription in brain of many genes [13] .
VPA also has been reported to block excitatory responses induced by N-methyl-D-aspartate (NMDA) in vivo and in vitro, NMDA-induced convulsions in vivo [37, 38, 47, 57, 91, 96] , and other aspects of brain glutamatergic activity [50, 78, 89, 92] . In view of evidence of upregulated or otherwise disturbed brain glutamatergic neurotransmission in patients with bipolar disorder [41, 50, 59 , 90], we thought it of interest to see whether VPA could interfere with NMDA receptor initiated signaling involving the second messenger, arachidonic acid (AA, 20:4n -6). AA and its metabolites have multiple effects, including regulation of neuronal activity, gene transcription, apoptosis, sleep and cerebral blood flow [49, 58, 81] .
Binding of glutamate or of NMDA to NMDA receptors will increase intracellular Ca 2+ , thereby activating Ca 2+ -dependent enzymes including AA-selective cytosolic phospholipase A 2 (cPLA 2 ). cPLA 2 activation releases unesterified AA from the stereospecifically numbered-2 position of membrane phospholipid, which leads to increased formation via cyclooxygenase (COX) enzymes of eicosanoids such as prostaglandin E 2 (PGE 2 ) and thromboxane B 2 (TXB 2 ) [33, 46, 52, 79, 87, 93] . We have developed an in vivo method to image this activation process, and decided to use the method to image the effect of chronic VPA in rats on the NMDA receptor-mediated AA signal [5] . Prior reports indicate that other mood-stabilizers, lithium and carbamazepine, when given chronically to rats block this NMDA-mediated AA signal [5, 9] .
The method to measure the AA signal involves infusing radiolabeled [1- 14 C]AA intravenously following administration of drug or vehicle, imaging regional brain radioactivity after 15 min with quantitative autoradiography, and converting these images into regional AA incorporation coefficients k*. k* represents the AA that has been released during the signal and metabolized to eicosanoids and other products and is independent of changes in cerebral blood flow [28, [74] [75] [76] .
In this study, we measured k* for AA in 82 brain regions of unanesthetized rats that had been injected with VPA (200 mg/kg i.p.) or vehicle (saline) daily for 30 days as described [22] . These rats were injected i.p. acutely with a subconvulsant dose (25 mg/kg) of NMDA [5, 65] or with saline. Whole brain concentrations of PGE 2 and TXB 2 also were measured.
Experimental Procedures

Animals and Diets
Experiments were conducted following the ''Guide for the Care and Use of Laboratory Animals'' (National Institutes of Health Publication No. 86-23) and were approved by the Animal Care and Use Committee of the National Institute of Child Health and Development. Two-month-old male Fischer CDF (F-344)/CrlBR rats (Charles River Laboratories, Wilmington, MA, USA) were acclimatized for 1 week in an animal facility with regulated temperature, humidity and light cycle, and had ad libitum access to food (NIH-31 diet, Zeigler, Gardners, PA, USA) and water. The diet contained (as percent of total fatty acids) 20.1% saturated, 22.5% monounsaturated, 47.9% linoleic, 5.1% a-linolenic, 0.02% AA, 2.0% eicosapentaenoic, and 2.3% docosahexaenoic acid.
Drugs and Tracers [1- 14 C]AA in ethanol (53 mCi/mmol, [98% pure, Moravek Biochemicals, Brea, CA, USA) was evaporated and resuspended in HEPES buffer, pH 7.4, containing 50 mg/ ml fatty acid-free bovine serum albumin (Sigma-Aldrich, St Louis, MO, USA). NMDA (25 mg/kg, Sigma-Aldrich) or saline was administered i.p. The NMDA dose has been reported to produce paroxysmal spikes and spike trains but not status epilepticus in rats [65] and to significantly increase k* for AA [5, 9] . VPA-treated rats received 200 mg/kg i.p. VPA (sodium salt; Sigma-Aldrich) in saline once daily for 30 days, as previously described [12, 14, 22, 73] . Three hours after the last VPA injection, the plasma VPA concentration equals 31 ± 6 (mean ± SD) lg/ml [22], slightly below the therapeutic range (45-150 lg/ml) for bipolar disorder [35] . A control group received the same volume of saline (vehicle) under parallel conditions.
Surgical Procedures and Tracer Infusion
On the morning following the 30th VPA or vehicle injection, a rat was anesthetized with 2-3% halothane in O 2 , and PE 50 polyethylene catheters were inserted into the right femoral artery and vein as described previously [5] . The wound was closed with surgical clips and the rat was wrapped loosely, with its upper body remaining free, in a fast-setting plaster cast (DePuy Inc., Raynam, MA, USA) that was taped to a wooden block. Surgery lasted 20-25 min. The rat was allowed to recover from anesthesia for 3 h in a quiet environment maintained at 25°C. Body temperature was maintained at 36.4-37.1°C using a feedback heating device and rectal thermometer. Arterial blood pressure and heart rate were measured with a blood pressure recorder (CyQ 103/302; Cybersense, Inc., Nicholasville, KY, USA). Arterial blood pH, pO 2 and pCO 2 were measured with a blood gas analyzer (Rapidlab 248, Bayer Health Care Diagnostics Division, Norwood MA, USA).
Ten minutes after injecting NMDA or saline, 2 ml [1-
14 C]AA (170 lCi/kg) was infused into the femoral vein for 5 min at a rate of 400 ll/min using an infusion pump (Harvard Apparatus Model 22, Natick, MA, USA). Twenty minutes after starting the infusion, the rat was euthanized with an overdose of Nembutal Ò (90 mg/kg, i.v.) and decapitated. The brain was removed in less than 30 s, frozen in 2-methylbutane maintained at -40°C with dry ice, and stored at -80°C until sectioned. Thus, brains were sampled within 4 h after the last daily VPA injection.
Chemical Analysis
Thirteen arterial blood samples collected before, during and after [1- 14 C]AA infusion were centrifuged immediately (30 s at 18,000g). Total lipids were extracted from 30 ll of plasma with 3 ml chloroform:methanol (2:1, by vol) and 1.5 ml 0.1 M KCl using Folch procedure [34] . Radioactivity was determined in 100 ll of the lower organic phase by liquid scintillation counting. As reported [26] , greater than 97% of plasma radioactivity at 5 min following [1- 14 C]AA infusion was radiolabeled AA, and brain phospholipids accounted for greater than 81% of brain lipid radioactivity over 2 h, whereas aqueous metabolites of AA account for 10% at 5 min and decrease with time.
Quantitative Autoradiography
Frozen brains were cut in serial 20-lm thick coronal sections in a cryostat at -20°C. The sections were placed for 5 weeks together with calibrated [
14 C]methylmethacrylate standards on Kodak Ektascan C/RA film (Eastman Kodak Company, Rochester, NY, USA). Brain regions from autoradiographs were identified from a stereotaxic rat brain atlas [67] , and were sampled in both hemispheres. The average of bilateral measurements for each region from three consecutive brain sections was used to calculate regional radioactivity (nCi/g of brain) by digital quantitative densitometry, using a Macintosh computer and the public domain NIH Image program 1.62 (developed at the U.S. National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/). Regional incorporation coefficients k* (ml plasma/s/g brain) of AA were calculated as [76] ,
c Ã plasma equals plasma radioactivity determined by scintillation counting (nCi/ml), c Ã brain equals brain radioactivity (nCi/g brain), and t equals time after starting [1- 14 C]AA infusion.
Brain Prostaglandin E 2 and Thromboxane B 2 
Concentrations
In separate experiments, 3 h and 45 min after the last of 30 daily injections of VPA or vehicle, a rat was injected i.p. with NMDA (25 mg/kg) or saline. Ten minutes later, it was anesthetized with Nembutal Ò (45 mg/kg, i.p.) and immediately subjected to head-focused microwave irradiation (5.5 kW, 3.8 s; Cober Electronics, Stamford, CT, USA) to stop brain metabolism [15, 30] . Half-brains were weighed, homogenized with 18 volumes of hexane:isopropanol (3:2, by vol) using a glass Tenbroeck homogenizer and the homogenate was centrifuged for 5 min at 800g. Tissue residues were rinsed with 3 9 2 volumes of the same solvent. The resultant lipid extract was concentrated to dryness under nitrogen and resuspended in the enzyme immunoassay buffer provided with the polyclonal PGE 2 and TXB 2 kits (Oxford Biochemical Research, Oxford, MI, USA).
Statistical Analyses
An unpaired two-tailed t-test was used to compare mean physiological parameters in chronic VPA-and vehicletreated rats, using GraphPad Prism version 4.0b (GraphPad Software, San Diego, CA, USA, www.graphpad.com). A standard two-way analysis of variance (ANOVA) was performed with SPSS 11.0 (SPSS Inc., Chicago, IL, USA, http://www.spss.com), to compare chronic VPA-versusvehicle with acute NMDA-versus-saline with regard to arterial plasma radioactivity input functions, brain PGE 2 and TXB 2 concentrations and regional values of k*. Where interactions between VPA and NMDA were statistically insignificant, probabilities of effects of VPA and NMDA were reported. Where the interactions were significant, probabilities of main effects of VPA and NMDA were not reported [85] . Instead, unpaired two-tailed t-tests were used to compare NMDA and saline responses between chronic VPA-and vehicle-treated rats as well as saline responses in VPA-compared with vehicle-treated rats. Other comparisons were not considered relevant. A post-hoc test was not used to avoid a correction for multiple comparisons. Data are reported as the mean ± SD, with statistical significance taken as P B 0.05.
Results
Physiology, Behavior and Arterial Plasma Radioactivity
Rats injected daily with VPA for 30 days weighed significantly less than vehicle-treated rats (Table 1 ). In chronic vehicle-treated rats, acute NMDA (25 mg/kg) produced repeated cycles of activity (head weaving and body movements) lasting on average 4 s, following by a ''calm'' period averaging 9 s, with the net cycling period lasting a mean of 95 s ( Table 1 ). The mean durations of the behavioral parameters were not significantly different in chronic VPA-treated rats. Compared with acute saline, NMDA did not significantly affect arterial pH, pCO 2 , pO 2 or blood pressure, but significantly decreased heart rate by 21-23% in both chronic vehicle-and VPA-treated groups (Table 1) , as previously reported [5] . Neither chronic VPA nor acute NMDA modified the time-course of arterial plasma radioactivity (Eq. 1) following intravenous [1- 14 C]AA infusion. The mean integral of radioactivity in the plasma organic fraction, (nCi 9 s)/ ml (n = 6), did not differ significantly between groups: chronic vehicle plus saline, 180, 783 ± 24,145; chronic vehicle plus NMDA, 170,249 ± 16,855; VPA plus saline, 162,752 ± 18,879; VPA plus NMDA, 149,555 ± 21,089.
Regional Brain AA Incorporation Coefficients, k* Figure 1 presents coronal autoradiographs of brains from rats given saline or NMDA after chronic vehicle or VPA. Values of k* for AA, calculated by Eq. 1, are color-coded. The figure shows no apparent difference in regional values of k* in response to saline between the animals treated chronically with VPA compared with vehicle (both given acute saline). Acute NMDA increased k* in many gray matter regions of the chronic vehicle-treated rat, but had no evident effect on k* in the VPA-treated rat. Data obtained from such autoradiographs are summarized in Table 2 and Fig. 2 .
Effects of NMDA in Chronic Vehicle-treated Rats
Mean values of k* in each of 82 brain regions were subjected to a two-way ANOVA, as illustrated in Table 2 . Statistically significant interactions between VPA and NMDA were found in 41, in which unpaired t-tests then showed that NMDA compared with saline significantly increased k* by 19-61% in chronic vehicle-treated rats. Affected regions included prefrontal (38-41%), frontal (34-45%), primary olfactory (28%), anterior cingulate (61%), motor (35-46%), somatosensory (31-35%), auditory layer I (40%) and visual cortical areas (40-55%), hippocampus [CA1, CA2, CA3, dentate gyrus, stratum lacunosum-molecular] (19-38%), nucleus accumbens (22%), caudate-putamen (26-34%), lateral geniculate nucleus dorsal (27%), thalamus [paratenial, anteroventral and parafascicular nuclei] (25-37%), interpeduncular nucleus (28%), substantia nigra (40%), inferior colliculus (23%), and cerebellar gray matter (23-30%). The overall pattern of differences due to NMDA compared with saline in chronic vehicle-treated rats is illustrated in Fig. 2a .
Effects of Chronic Valproic Acid at Baseline
In the 41 regions in which VPA 9 NMDA interactions were statistically significant, chronic VPA compared with chronic vehicle significantly changed mean baseline (post-saline) k* in three of them (Table 2 )-frontal cortex (10) layer IV (16%), motor cortex layer V (19%) and interpeduncular nucleus (-15%). In the other 41 regions in which VPA 9 NMDA interactions were statistically insignificant, chronic VPA had a main effect in five of them, but reduced k* only in the olfactory tubercle. Thus, chronic VPA altered baseline k* in 4 of the 82 brain regions studied. The overall pattern of differences due to chronic VPA compared with chronic saline is illustrated in Fig. 2b .
Effects of Acute NMDA in Valproic Acid-treated Rats
NMDA compared with saline changed k* significantly (-12%) in only one of the 41 regions in which VPA 9 NMDA interactions were statistically significant, frontal cortex (10) layer IV ( Table 2) . Acute NMDA did not significantly affect k* in any of the 41 regions in which VPA 9 NMDA interactions were statistically insignificant. In none of these latter regions did NMDA have a main effect on k*. The absence of a significant NMDA effect in animals pretreated with VPA is illustrated in Fig. 2c .
Brain PGE 2 and TXB 2 Concentrations
A two-way ANOVA demonstrated statistically significant interactions between VPA and NMDA with regard to brain PGE 2 and TXB 2 concentrations (Table 3) . Consequent t-tests showed that chronic VPA alone significantly decreased basal concentrations of PGE 2 by 66% and of TXB 2 by 45%. Acute NMDA increased PGE 2 and TXB 2 concentrations in chronic vehicle-treated rats, but did not significantly affect either concentration in chronic VPAtreated rats.
Discussion
Consistent with reports that VPA interferes with glutamatergic function and NMDA receptor signaling (see 'Introduction'), daily administration of VPA to rats for 30 days, at a dose that produces a plasma VPA concentration relevant to bipolar disorder, prevented the statistically significant increases in AA incorporation coefficients k*, and in whole brain PGE 2 and TXB 2 concentrations, that were caused by a subconvulsant acute dose of NMDA in chronic vehicle-treated rats. To the extent that glutamatergic signaling via NMDA receptors is pathologically upregulated in bipolar disorder patients, for which evidence exists (see 'Introduction') [41, 50, 59, 90] , these results suggest that VPA's efficacy in the disease is due in part to its ability to dampen upregulated NMDA signaling involving AA and its downstream metabolites. Chronic administration to rats of lithium or carbamazepine, resulting in therapeutic relevant plasma concentrations, also dampen NMDA-induced elevations in k* for AA and in brain eicosanoid [5, 9] . Thus, reduced NMDA signaling involving AA and its metabolites may be common to the therapeutic action of mood-stabilizers in bipolar disorder. Evidence that cholinomimetics [19] as well as drugs that interfere with dopaminergic [24, 60, 68, 71] or glutamatergic [2, 61, 88] signaling ameliorate bipolar disorder symptoms, and of defective serotonergic signaling in the disease [56] , has suggested that bipolar symptoms reflect reduced cholinergic, altered serotonergic, and increased dopaminergic and glutamatergic neurotransmission. Our studies in rats now suggest that chronic VPA, lithium and carbamazepine as a group can correct this imbalance, and that the imbalance involves AA as a second messenger [4-9, 21, 77] .
Our values of k* in this study agree with published values [5, 9] . NMDA increased k* significantly in 41 of 82 brain structures with high densities of NMDA receptors [66] , including the cerebral cortex, caudate-putamen, globus pallidus, hippocampus, thalamus, hypothalamus, colliculus, substantia nigra. Our measured PGE 2 and TXB 2 concentrations agree with other studies showing elevated brain concentrations of these eicosanoids following acute NMDA [9, 64, 69] and reduced concentrations following chronic VPA [14, 84] . Concentrations of PGD 2 and PGF 2a also were increased after NMDA [51, 54] but were decreased by chronic VPA [84] .
VPA's ability to suppress NMDA-induced increases in k* for AA and to reduce PGE 2 and TXB 2 concentrations could have been due to its ability to reduce COX-1 and COX-2 expression or interfere directly with the NMDA receptor [14, 73] . When COX enzymes are pharmacologically inhibited or knocked out in rodent brain, k* responses to drugs acting at cPLA 2 -coupled neuroreceptors are reduced or lost, as are the increases in brain PGE 2 and/or TXB 2 concentrations [10, 11] . VPA can inhibit cyclic AMP-dependent protein kinases A and C, both of which can phosphorylate the NMDA receptor [32, 53, 94] . VPA also can reduce expression of two NMDA receptor-interacting proteins in rat brain, postsynaptic density protein PSD-95, which is altered in bipolar disorder [90] , and type II Ca 2+ /calmodulin-dependent protein kinase beta subunit [13] . It inhibits histone deacetylase, which acetylates the NMDA receptor transcription factor, specificity protein-1 (Sp1) [3, 70] , and can reduce methylation of the reelin gene, which encodes a protein that regulates NMDA receptor surface trafficking and synaptic Each value is a mean ± SD (n = 4). * P \ 0.01, ** P \ 0.001; vehicle plus NMDA versus vehicle plus saline, valproate plus saline versus vehicle plus saline, valproate plus NMDA versus valproate plus saline [20, 36] , decreases basal glutamate release, and increases glutamate uptake in brain [42, 89, 92] . VPA also may modulate neurotransmission involving cPLA 2 and AA coupled to glutamatergic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors [25, 32, 38, 48, 93] . The behavioral effects of NMDA (Table 1) are not altered qualitatively by chronic VPA, lithium [5] or carbamazepine [9] . Thus, AA signaling via NMDA receptors likely does not contribute to these effects. In agreement, neither VPA, lithium or carbamazepine modified the seizure threshold to NMDA in rodents [65, 82] , and VPA did not reduce NMDA-induced running/jumping fits, clonictonic seizure or mortality in rats [44] . NMDA also can promote synaptic release of acetylcholine, adenosine, serotonin and c-aminobutyric acid [27, 86, 93, 95] .
Since mood-stabilization in bipolar patients appears only after 10 days of oral VPA [16] , we as have others [5, 9, 12, 13, 18, 22, 42, 55] studied effects only of chronic VPA in rats. An acute injection of VPA (300 mg/kg) in rats did not alter basal or stimulated extracellular glutamate in the hippocampus, whereas chronic VPA decreased whole brain glutamate concentration [1, 63] . Chronic but not acute VPA administration changed corticotropin releasing factor [83] and AMPA glutamate receptors [32] in rat brain.
In conclusion, chronic VPA pretreatment prevented the statistically significant increases in k* for AA and in PGE 2 and TXB 2 concentrations that were observed in response to NMDA in chronic vehicle-treated rats. These and observations in rats administered chronic lithium or carbamazepine support the hypothesis that mood stabilizers commonly downregulate brain AA signaling via NMDA receptors. 
